<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328325</url>
  </required_header>
  <id_info>
    <org_study_id>16-0101</org_study_id>
    <secondary_id>HHSN272201400005C</secondary_id>
    <nct_id>NCT03328325</nct_id>
    <nct_alias>NCT03133936</nct_alias>
  </id_info>
  <brief_title>Age and Response to Flu Vaccines</brief_title>
  <official_title>Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on the B Cell Response to Inactivated Influenza Vaccine in Healthy Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be designed as a prospective surveillance of the immune response to seasonal&#xD;
      influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will&#xD;
      be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent&#xD;
      inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by&#xD;
      intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline,&#xD;
      day 7, 28 and 90. The primary objective of this study is to evaluate the relationship between&#xD;
      first influenza A virus exposure (inferred by age), vaccine history, and baseline serum&#xD;
      antibody response to seasonal influenza vaccine in healthy adults and children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be designed as a prospective surveillance of the immune response to seasonal&#xD;
      influenza vaccination in 240 healthy children and adults ages 9 and over. Study duration will&#xD;
      be 5 years, with a participant duration of 6 months. Subjects will receive a quadrivalent&#xD;
      inactivated influenza vaccine, at a dose of not less than 15 ug of hemagglutinin (HA), by&#xD;
      intramuscular injection in open label fashion on day 0. Blood draws will occur at baseline,&#xD;
      day 7, 28 and 90. The primary hypothesis being tested in this study is that there will be&#xD;
      differences in the specificity and magnitude of the HA-specific B cell response depending on&#xD;
      the age, previous vaccine history and baseline B cell reactivity. The primary objective of&#xD;
      this study is to evaluate the relationship between first influenza A virus exposure (inferred&#xD;
      by age), vaccine history, and baseline serum antibody response to seasonal influenza vaccine&#xD;
      in healthy adults and children. The secondary objective is to evaluate factors related to&#xD;
      failure of vaccine to provide protection against symptomatic influenza and the immune&#xD;
      response to infection in vaccinated individuals by prospective surveillance of the vaccine&#xD;
      cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 9, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</measure>
    <time_frame>Through Day 28</time_frame>
    <description>A/Hong Kong/4801/2014 (H3N2) day 28 Season 2017-2018</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of the Serum Antibody Response by Microneutralization (MN)</measure>
    <time_frame>Day 28</time_frame>
    <description>A/Hong Kong/4801/2014 (H3N2) Day 28 MN Season 2017-2018</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Antibody Response by Hemagglutination-inhibition (HAI)</measure>
    <time_frame>Day 90</time_frame>
    <description>A/Hong Kong/4801/2014 (H3N2) Day 90 Season 2017-2018</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Antibody Response by Microneutralization (MN)</measure>
    <time_frame>Day 90</time_frame>
    <description>A/Hong Kong/4801/2014 (H3N2) Day 90 MN Season 2017-2018</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</measure>
    <time_frame>Day 28</time_frame>
    <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-2018</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the Serum Antibody Response by Microneutralization (MN)</measure>
    <time_frame>Day 28</time_frame>
    <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-18</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age at Time of First Influenza A Exposure</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline B Cell Reactivity</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine History (Number and Percentage of Participants to Receive Vaccine)</measure>
    <time_frame>Baseline</time_frame>
    <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza Immunisation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Quadrivalent Inactivated Vaccine</intervention_name>
    <description>A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Quadrivalent Inactivated Vaccine</intervention_name>
    <description>A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged equal to or greater than 9 years of age and weigh at least 50 pounds&#xD;
&#xD;
          2. The subject must be in good health, as determined by: medical history; and targeted&#xD;
             physical examination, when necessary, based on medical history. Stable medical or&#xD;
             psychiatric condition is defined as: no recent increase in prescription medication,&#xD;
             dose, or frequency of medication in the last 3 months and health outcomes of the&#xD;
             specific disease are considered to be within acceptable limits in the last 6 months&#xD;
&#xD;
          3. The subject is able to understand and comply with the planned study procedures,&#xD;
             including being available for all study visits&#xD;
&#xD;
          4. The subject/parent has provided informed consent/assent prior to any study procedures&#xD;
&#xD;
          5. Subjects who have not received seasonal flu vaccine for the current year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject report of known hypersensitivity to allergy to components of the study vaccine&#xD;
             or other components of the study vaccine&#xD;
&#xD;
          2. Subject report of known latex allergy&#xD;
&#xD;
          3. Subject report of a history of severe reactions following previous immunization with&#xD;
             licensed or unlicensed influenza virus vaccines&#xD;
&#xD;
          4. Subject report of a history of Guillain-Barre syndrome within 6 weeks of receipt of a&#xD;
             previous influenza vaccine&#xD;
&#xD;
          5. The subject is a female of childbearing potential who is currently pregnant or&#xD;
             breastfeeding or intends to become pregnant during the study period between enrollment&#xD;
             and 90 days following receipt of vaccine. Pregnancy will be determined by subject&#xD;
             interview. Pregnancy testing is not done in this study since there is no increased&#xD;
             risk in pregnancy&#xD;
&#xD;
          6. The subject is immunosuppressed as a result of an underlying illness or treatment with&#xD;
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation&#xD;
             therapy within the preceding 36 months&#xD;
&#xD;
          7. The subject has an active neoplastic disease (excluding non-melanoma skin cancer or&#xD;
             prostate cancer that is stable in the absence of therapy) or a history of any&#xD;
             hematological malignancy. For this criterion, &quot;active&quot; is defined as having received&#xD;
             treatment within the past 5 years&#xD;
&#xD;
          8. Have taken high-dose inhaled corticosteroids within 30 days prior to study&#xD;
             vaccination. High-dose defined as per age as using inhaled high dose per reference&#xD;
             chart&#xD;
             https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/quick-refere&#xD;
             nce-html#estimated-comparative-daily-doses&#xD;
&#xD;
          9. The subject received immunoglobulin or another blood product within the 3 months prior&#xD;
             to enrollment in this study&#xD;
&#xD;
         10. The subject has received an inactivated vaccine within the 2 weeks or a live vaccine&#xD;
             within the 4 weeks prior to enrollment in this study or plans to receive another&#xD;
             vaccine within the next 28 days after vaccination&#xD;
&#xD;
         11. The subject has an acute or chronic medical condition that, in the opinion of the&#xD;
             investigator or appropriate sub-investigator, would render vaccination unsafe or would&#xD;
             interfere with the evaluation of responses. These conditions include any acute or&#xD;
             chronic medical disease or conditions defined as persisting for 3 months (defined as&#xD;
             90 days) or longer, that would place the subject at an unacceptable risk of injury,&#xD;
             render the subject unable to meet the requirements of the protocol, or may interfere&#xD;
             with the evaluation of responses of the subject's successful completion of the study&#xD;
&#xD;
         12. Subjects with an active infection or that has an acute illness or an oral temperature&#xD;
             greater than 99.9 degrees Fahrenheit (37.7 degrees Celsius) within 3 days prior to&#xD;
             enrollment or vaccination. Subjects who had an acute illness that was treated symptoms&#xD;
             resolved are eligible to enroll as long as treatment is completed and symptoms&#xD;
             resolved &gt; 3 days prior to enrollment&#xD;
&#xD;
         13. The subject is currently participating or plans to participate in a study that&#xD;
             involves an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) or has received an experimental agent within 1 month prior to enrollment&#xD;
             in this study, or expects to receive another experimental agent during participation&#xD;
             in this study, or intends to donate blood during the study period&#xD;
&#xD;
         14. The subject has any condition that would, in the opinion of the site investigator,&#xD;
             place the subject at an unacceptable risk of injury or render the subject unable to&#xD;
             meet the requirements of the protocol&#xD;
&#xD;
         15. The subject has a history of alcohol or drug abuse in the 5 years prior to enrollment&#xD;
&#xD;
         16. The subject has a known human immunodeficiency virus, hepatitis B, or hepatitis C&#xD;
             infection&#xD;
&#xD;
         17. Subject weighs less than 50 lbs&#xD;
&#xD;
         18. Subject expects to have a medical procedure during the upcoming 8 weeks that estimates&#xD;
             blood loss to exceed 400 cc for adults or for children would exceed 3 ml/kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rochester General Hospital - Infectious Disease Unit</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621-3001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 3, 2021</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <results_first_submitted>April 29, 2021</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2021</results_first_posted>
  <disposition_first_submitted>February 5, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 9, 2021</disposition_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B Cell Response</keyword>
  <keyword>Children</keyword>
  <keyword>Evaluation</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 25, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03328325/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adults and children ages 9 and over</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Study Termination due to COVID-19 pandemic</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="9" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
        <description>A/Hong Kong/4801/2014 (H3N2) day 28 Season 2017-2018</description>
        <time_frame>Through Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
          <description>A/Hong Kong/4801/2014 (H3N2) day 28 Season 2017-2018</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Magnitude of the Serum Antibody Response by Microneutralization (MN)</title>
        <description>A/Hong Kong/4801/2014 (H3N2) Day 28 MN Season 2017-2018</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnitude of the Serum Antibody Response by Microneutralization (MN)</title>
          <description>A/Hong Kong/4801/2014 (H3N2) Day 28 MN Season 2017-2018</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="806" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
        <description>A/Hong Kong/4801/2014 (H3N2) Day 90 Season 2017-2018</description>
        <time_frame>Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
          <description>A/Hong Kong/4801/2014 (H3N2) Day 90 Season 2017-2018</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Antibody Response by Microneutralization (MN)</title>
        <description>A/Hong Kong/4801/2014 (H3N2) Day 90 MN Season 2017-2018</description>
        <time_frame>Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Antibody Response by Microneutralization (MN)</title>
          <description>A/Hong Kong/4801/2014 (H3N2) Day 90 MN Season 2017-2018</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1389" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
        <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-2018</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI)</title>
          <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-2018</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="665" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity of the Serum Antibody Response by Microneutralization (MN)</title>
        <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-18</description>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of the Serum Antibody Response by Microneutralization (MN)</title>
          <description>A/H1N1/Michigan/45/2015 pdm09 Day 28 Season 2017-18</description>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2281" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age at Time of First Influenza A Exposure</title>
        <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline B Cell Reactivity</title>
        <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine History (Number and Percentage of Participants to Receive Vaccine)</title>
        <description>Comparison between groups: subjects who develop symptomatic influenza (Vaccine Failures) vs. subjects who do not</description>
        <time_frame>Baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.&#xD;
Influenza Virus Quadrivalent Inactivated Vaccine: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 [H1N1] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric Mass, S/P Wedge resection, GIST Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Branche, MD, Site Principal Investigator</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-275-5871</phone>
      <email>angela_branche@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

